CN115404187A - Probiotic composition for weight management and decompression - Google Patents
Probiotic composition for weight management and decompression Download PDFInfo
- Publication number
- CN115404187A CN115404187A CN202211124400.4A CN202211124400A CN115404187A CN 115404187 A CN115404187 A CN 115404187A CN 202211124400 A CN202211124400 A CN 202211124400A CN 115404187 A CN115404187 A CN 115404187A
- Authority
- CN
- China
- Prior art keywords
- probiotic composition
- parts
- probiotic
- weight
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 83
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 83
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 70
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 230000037221 weight management Effects 0.000 title claims abstract description 19
- 230000006837 decompression Effects 0.000 title description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 26
- 241001134770 Bifidobacterium animalis Species 0.000 claims abstract description 21
- 229940118852 bifidobacterium animalis Drugs 0.000 claims abstract description 21
- 240000000696 Lactobacillus helveticus R0052 Species 0.000 claims abstract description 17
- 235000005877 Lactobacillus helveticus R0052 Nutrition 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 10
- 235000013361 beverage Nutrition 0.000 claims description 9
- 235000009508 confectionery Nutrition 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 17
- 230000000968 intestinal effect Effects 0.000 abstract description 13
- 230000037406 food intake Effects 0.000 abstract description 8
- 230000001276 controlling effect Effects 0.000 abstract description 7
- 206010020710 Hyperphagia Diseases 0.000 abstract description 6
- 210000004556 brain Anatomy 0.000 abstract description 6
- 230000020595 eating behavior Effects 0.000 abstract description 6
- 235000020830 overeating Nutrition 0.000 abstract description 6
- 230000009467 reduction Effects 0.000 abstract description 6
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 235000021407 appetite control Nutrition 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 235000011888 snacks Nutrition 0.000 abstract description 3
- 206010056465 Food craving Diseases 0.000 abstract description 2
- 235000013376 functional food Nutrition 0.000 abstract description 2
- 230000037356 lipid metabolism Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 17
- 229940068196 placebo Drugs 0.000 description 10
- 239000000902 placebo Substances 0.000 description 10
- 239000002994 raw material Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 235000019789 appetite Nutrition 0.000 description 6
- 230000036528 appetite Effects 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 5
- 240000002605 Lactobacillus helveticus Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000009102 absorption Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000012631 food intake Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229940054346 lactobacillus helveticus Drugs 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000019577 caloric intake Nutrition 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 241001608472 Bifidobacterium longum Species 0.000 description 3
- 206010004716 Binge eating Diseases 0.000 description 3
- 208000032841 Bulimia Diseases 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 241000186605 Lactobacillus paracasei Species 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 229940009291 bifidobacterium longum Drugs 0.000 description 3
- 208000014679 binge eating disease Diseases 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 235000013325 dietary fiber Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000019627 satiety Nutrition 0.000 description 3
- 230000036186 satiety Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000001599 crocus sativus l. flower extract Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000021061 dietary behavior Nutrition 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 229940076591 saffron extract Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000004260 weight control Methods 0.000 description 2
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000193171 Clostridium butyricum Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000598860 Garcinia hanburyi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 229940117709 gamboge Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 235000020887 ketogenic diet Nutrition 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000020938 metabolic status Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 235000003784 poor nutrition Nutrition 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000014107 unsaturated dietary fats Nutrition 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 229940054810 white kidney bean extract Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/366—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a probiotic composition for weight management and pressure reduction, and relates to the field of functional foods, wherein the probiotic composition comprises lactobacillus rhamnosus HA-114, lactobacillus helveticus R0052 and bifidobacterium animalis Lafti B94. The composition disclosed by the invention is mainly used for regulating and controlling the brain and intestinal axis through probiotics, specially aiming at the involuntary eating behaviors of people after bearing pressure, including overeating, snack ingestion, sugar craving and the like, and achieving a better weight-losing effect by improving the subjective appetite control capability of people and promoting lipid metabolism.
Description
Technical Field
The invention relates to the field of functional foods, in particular to a probiotic composition for weight management and decompression.
Background
Obesity generally refers to the pathological and physiological changes of the human body caused by excessive food intake or metabolic changes of the body, which leads to excessive fat accumulation in the body. Obesity not only can bring about changes of body morphology, but also can improve the incidence of chronic diseases such as diabetes, coronary heart disease and the like. The current weight management approaches can be broadly divided into several directions: reducing energy intake, such as controlling food intake, regulating appetite, etc.; reducing energy absorption in the body, such as blocking carbohydrate or fat absorption, etc.; increase energy expenditure, such as exercise planning, promotion of fat consumption, etc.; alter energy metabolism, such as ketogenic diet. Recent researches gradually suggest that the brain intestinal axis involved in human intestinal flora can also regulate and control eating behaviors, thereby influencing the development of obesity. Stress can affect flora and the brain and intestine axis, change the levels of cortisol, insulin, neuropeptide Y and other related hormones in vivo, improve the satisfaction brought by energy intake, and prompt people to select a placebo food with high calorie, high sugar and high fat. On the other hand, ingestion of a placebo food product may activate the brain reward system, thereby reducing cognitive control ability. Studies published in the Science journal by the research team at the Pasteur institute, france, 2022 showed that hypothalamic neurons could directly sense changes in intestinal bacterial activity and adjust appetite and body temperature accordingly. Sims R et al demonstrated a clear link between the perceived stress and weight gain and abdominal fat; a link between stress and emotional eating behavior was also established, particularly with increased sweet snacks in obese subjects.
Tremblay and colleagues studied the effect of stress on energy intake: after completion of the stress task, the energy intake of the girl student is higher.
Since overweight and obese patients are often under a variety of stress sources, such as physical, health concerns and difficulty in managing weight, these stress sources are prone to causing stress feeding that affects the performance of weight loss programs. Therefore, controlling the additional intake of calories would be a precondition for all weight loss programs.
The existing part of functional components have the effect of controlling appetite, but poor nutrition and insufficient heat are easily caused by simply controlling the appetite, the functional components become a pressure source for organisms, the self-control ability is easily broken through at a certain moment to begin to report the sexual overeating, and the weight-losing plan is short of one step. In the prior art, probiotics are applied to products for weight management, but the probiotics generally only have the effects of assisting in regulating intestinal flora, promoting intestinal peristalsis, preventing constipation and the like, and do not directly aim at weight management or appetite control (CN 112544967A, CN 112868802A, CN 109998096A and the like); CN 110403014A discloses a nutritional powder comprising skim milk, whey protein powder, unsaturated fatty acid, prebiotics, dietary fiber, short chain fatty acid and active probiotic freeze-dried powder, which has effect of suppressing appetite. However, the formula contains a large amount of components with satiety, such as protein, dietary fiber and the like, besides the probiotics, and the effect of the probiotics is not clearly embodied. CN 109924506A discloses a probiotic composition with weight-losing function, wherein the effective components are lactobacillus paracasei and metabolites of lactobacillus paracasei, but the strains in the invention are not related; CN 110151796A discloses a probiotic composition, which regulates the gene pattern of intestinal flora by changing the composition of intestinal microorganisms, so as to achieve the change of transcriptome, proteome and metabolome of intestinal flora, and further affect the digestion, absorption and metabolic processes of the host to affect the weight of the host. The composition contains a plurality of bacterial strains including Bifidobacterium lactis, bifidobacterium longum, lactobacillus reuteri, lactobacillus rhamnosus, lactobacillus acidophilus, streptococcus thermophilus, bacillus coagulans and Clostridium butyricum. The specific mechanism is not clarified, and the effect is achieved only by regulating the intestinal flora; CN113293118A discloses a lactobacillus rhamnosus strain LR3001, which has higher ability to inhibit activities of α -glucosidase and α -amylase, thereby reducing glucose absorption, and can be used in weight-reducing and blood sugar-lowering products, but its action mechanism is to reduce energy absorption in vivo.
Aiming at the defects of related products in the prior art, it is necessary to find a probiotic composition with continuity, good effect, difficult rebound weight management and pressure reduction.
Disclosure of Invention
Aiming at the problems in the prior art, the invention provides a probiotic composition for weight management and pressure reduction, the formula of the probiotic composition is mainly used for regulating and controlling the brain and intestinal axis through probiotics, specially aiming at the involuntary eating behaviors of people after bearing pressure, including overeating, snack ingestion, sugar craving and the like, and achieving a better weight-reducing effect by improving the subjective appetite control capability of people and promoting lipid metabolism, and the formula has a lasting effect, is simultaneously matched with various weight-reducing plans and is not easy to rebound.
In order to realize the purpose, the technical scheme adopted by the invention is as follows:
the invention provides a probiotic composition, which comprises lactobacillus rhamnosus HA-114, lactobacillus helveticus R0052 and bifidobacterium animalis Lafti B94.
Further, the probiotic composition comprises the following components in parts by weight: 50-120 parts of lactobacillus rhamnosus HA-114, 5-50 parts of lactobacillus helveticus R0052 and 5-50 parts of bifidobacterium animalis Lafti B94. The viable count of the probiotic composition is 60-200 hundred million CFU.
Preferably, the probiotic composition comprises the following components in parts by weight: 100 parts of lactobacillus rhamnosus HA-114, 30 parts of lactobacillus helveticus R0052 and 20 parts of bifidobacterium animalis Lafti B94. The probiotic composition has a viable count of 150 hundred million CFU.
Further, the invention also provides a preparation method of the probiotic composition, which comprises the following steps: mixing Lactobacillus rhamnosus HA-114, lactobacillus helveticus R0052, and Bifidobacterium animalis Lafti B94, stirring, and storing.
Further, the stirring speed is 18-22r/min, and the time is 20min.
In some embodiments, the method of preparing the probiotic composition comprises the steps of: weighing the three lyophilized strains at 20 + -2 deg.C under the condition of relative air humidity below 40%, mixing, stirring at 18-22r/min for 20min, and storing at 8 deg.C below.
Furthermore, the probiotic composition provided by the invention or prepared by the preparation method can be applied to preparation of weight management products.
Furthermore, the probiotic composition provided by the invention or prepared by the preparation method can be applied to preparation of a pressure-reducing product.
Further, the weight management product or the pressure reduction product comprises a beverage, a capsule or a candy.
Further, the beverage comprises a solid beverage.
The technical effects obtained by the invention are as follows:
1. at the present stage, few studies on weight management are realized through probiotics, the effects of promoting intestinal peristalsis and defecation are mainly realized through the probiotics in application, and other components with satiety or other fat reduction are combined to realize the weight management, but the invention has no great innovation in the study of the action mechanism of the probiotics;
2. although the three probiotics in the formula have the research in the fields of intestinal health, emotional health and the like, the three probiotics do not have obvious weight-losing effect when being used alone, and the three probiotics can achieve obvious weight-losing effect when being combined according to the proportion of the formula, so that the strains in the formula have the effect of synergistic effect.
3. Other probiotics such as bifidobacterium longum, lactobacillus plantarum, bifidobacterium bifidum, lactobacillus casei, lactobacillus paracasei, lactobacillus acidophilus and the like are added into the formula of the probiotic combination for matching; or plant extracts such as green coffee extract, saffron extract, potato extract, gamboge fruit extract, white kidney bean extract, lotus leaf extract and the like, or dietary fiber or oil and fat components such as Plantago ovata seed husk powder, konjak fine powder, medium chain triglyceride powder and the like can be added to promote satiety or control appetite, and the effect of controlling appetite can be realized by matching the components with the formula.
Drawings
FIG. 1 shows a probiotic group and a placeboBody indices of the group subjects; ordinate in the figure is T 0 -T 12 ；
FIG. 2 is the metabolic status of the probiotic and placebo subjects; ordinate in the figure is T 0 -T 12 ；
Figure 3 is stress status of subjects in the probiotic and placebo groups; the abscissa in the figure is T 0 -T 12 ；
Figure 4 is the eating behavior of the subjects in the probiotic and placebo groups; ordinate in the figure is T 0 -T 12 (ii) a In the figure, (one), (two) and (three) correspond to data related to cognitive restriction inhibition, uncontrolled feeding and hunger in a three-factor feeding questionnaire (TFEQ), respectively; and (IV) corresponding to the data related to the binge eating quantity questionnaire (BSQ).
Detailed Description
The embodiments of the present invention are described below with reference to specific embodiments, and other advantages and effects of the present invention will be easily understood by those skilled in the art from the disclosure of the present specification. The invention is capable of other and different embodiments and of being practiced or of being carried out in various ways, and its several details are capable of modification in various respects, all without departing from the spirit and scope of the present invention.
Before the present embodiments are further described, it is to be understood that the scope of the invention is not to be limited to the specific embodiments described below; it is also to be understood that the terminology used in the examples is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention.
When numerical ranges are given in the examples, it is understood that both endpoints of each of the numerical ranges and any number between the two endpoints are optional unless otherwise specified in the invention. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
It should be noted that the raw materials used in the present invention are all common commercial products, and thus the sources thereof are not particularly limited.
In the invention, the microorganism classification name of the Lactobacillus rhamnosus HA-114 is Lactobacillus rhamnosus, which is preserved in BCCM collection of Belgium and the preservation number is LMG S-24117.
Wherein, the microorganism classification name of the Lactobacillus helveticus R0052 is Lactobacillus helveticus, and the Lactobacillus helveticus R is preserved in national microorganism collection of Pasteur institute of France with the preservation number of I-1722.
The Bifidobacterium animalis Lafti B94 is classified as Bifidobacterium animalis lactis, is deposited in the Netherlands collection center, and has a deposit number of N118529.
The three bacteria suppliers are all Lallemand Health Solution of Raman company of Canada.
Example 1:
a probiotic composition for reducing stress overeating and aiding weight management, comprising: 100 parts of lactobacillus rhamnosus HA-114, 30 parts of lactobacillus helveticus R0052 and 20 parts of bifidobacterium animalis Lafti B94. The probiotic composition has a viable count of 150 hundred million CFU.
The preparation method comprises the steps of weighing lactobacillus rhamnosus HA-114, lactobacillus helveticus R0052 and bifidobacterium animalis Lafti B94 respectively, and then mixing and stirring for 25min at 20R/min to obtain the lactobacillus rhamnosus preparation. The whole preparation is carried out at a temperature of 20 +/-2 ℃ and a relative air humidity of less than 40%.
Example 2
A probiotic composition for reducing stress overeating and aiding weight management, comprising the following raw materials: 50 parts of lactobacillus rhamnosus HA-114, 5 parts of lactobacillus helveticus R005and 10 parts of bifidobacterium animalis Lafti B94. The probiotic composition has a viable count of 65 hundred million CFU.
The preparation method comprises the steps of weighing lactobacillus rhamnosus HA-114, lactobacillus helveticus R0052 and bifidobacterium animalis Lafti B94 respectively, and then mixing and stirring for 18min at 20R/min to obtain the lactobacillus rhamnosus preparation. The whole preparation is carried out at a temperature of 20 +/-2 ℃ and a relative air humidity of less than 40%.
Example 3
A probiotic composition for reducing stress overeating and aiding weight management, comprising: 100 parts of lactobacillus rhamnosus HA-114, 50 parts of lactobacillus helveticus R0052 and 50 parts of bifidobacterium animalis Lafti B94. The probiotic composition has a viable count of 200 hundred million CFU.
The preparation method comprises the steps of weighing lactobacillus rhamnosus HA-114, lactobacillus helveticus R0052 and bifidobacterium animalis Lafti B94 respectively, and then mixing and stirring for 20min at the speed of 20R/min to obtain the lactobacillus rhamnosus preparation. The whole preparation is carried out at a temperature of 20 +/-2 ℃ and a relative air humidity of less than 40%.
Comparative example 1
The difference between the comparative example and the example 1 is that the component proportion is different, specifically: lactobacillus rhamnosus HA-114 parts, lactobacillus helveticus R0052 parts, and Bifidobacterium animalis Lafti B94 parts. The probiotic composition has a viable count of 103 hundred million CFU.
Comparative example 2
The difference between the comparative example and the example 1 is that the strains are different, specifically: 100 parts of lactobacillus rhamnosus HA-114, 10 parts of lactobacillus helveticus Lafti L and 20 parts of bifidobacterium animalis Lafti B94. The probiotic composition has a viable count of 150 hundred million CFU.
Comparative example 3
The difference between the comparative example and the example 1 is that the probiotic composition comprises 100 parts of lactobacillus rhamnosus HA-114 and 50 parts of lactobacillus helveticus R0052.
Comparative example 4
The difference between the comparative example and the example 1 is that the probiotic composition comprises 100 parts of lactobacillus rhamnosus HA-114 and 50 parts of bifidobacterium animalis Lafti B94.
Comparative example 5
The difference between the comparative example and the example 1 is that the probiotic composition comprises lactobacillus helveticus R005275 parts and bifidobacterium animalis Lafti B94 parts.
Experimental example 1 probiotic composition weight control animal experiments
The experimental method comprises the following steps:
SD male rats with a body weight of 180-200g were selected and randomly and equally divided into an experimental group (examples 1-3 and comparative examples 1-5, total 8 groups), a high-fat control group and a normal control group, each group consisting of 10 animals. The experimental group and the high-fat control group are fed with high-fat feed, and the common control group is fed with common feed. The high-fat feed consists of 10 percent of lard, 10 percent of egg yolk powder and 80 percent of common feed.
The rats in the experimental group were subjected to intragastric administration with 10 intragastric administration dosage according to the corresponding probiotic composition water solution every day during the feeding period 8 CFU/day. The high-fat control group was gavaged with distilled water. The experimental period for weight loss was 8 weeks.
Detection indexes are as follows:
before the experiment, rats which are fasted for 12 hours are cut off tails and blood is taken, and serum Triglyceride (TG), total Cholesterol (TC), high density lipoprotein (HDL-C) and low density lipoprotein (LDL-C) are detected; weigh once a week during the experiment; recording the weight of the feed and the rest feed added every week, and calculating the average food intake; the rats were sacrificed 8 weeks later and the endpoint serum TG, TC, HDL-C, LDL-C was examined.
The experimental results are as follows:
TABLE 1
| Group of | Body weight | Food intake | TG | TC | HDL-C | LDL-C |
| General control group | 308.1 | 13.98 | 0.95 | 2.08 | 1.86 | 0.46 |
| High fat control group | 376.0 | 14.34 | 1.59 | 3.02 | 1.04 | 1.16 |
| Example 1 | 327.6** | 14.12* | 1.08** | 2.18** | 1.68** | 0.62** |
| Example 2 | 335.1** | 14.16 | 1.13** | 2.28** | 1.52** | 0.74** |
| Example 3 | 331.7** | 14.14 | 1.10** | 2.22** | 1.61** | 0.69** |
| Comparative example 1 | 344.7** | 14.22 | 1.17** | 2.35** | 1.45** | 0.84* |
| Comparative example 2 | 358.3* | 14.26 | 1.37* | 2.62* | 1.23* | 0.98* |
| Comparative example 3 | 351.5* | 14.27 | 1.24** | 2.76 | 1.37* | 1.04 |
| Comparative example 4 | 357.1* | 14.31 | 1.28* | 2.82 | 1.34* | 1.06 |
| Comparative example 5 | 370.5 | 14.30 | 1.41 | 2.53** | 1.22* | 0.91* |
Differences from the high fat control group showed: * P <0.05; * P <0.01
As shown in the above table, after the probiotic is fed for 8 weeks by the high-fat feed, the weight and the blood lipid level of the high-fat control group are significantly changed compared with the common control group, the weight and the blood lipid level of the rats fed with the probiotic in examples 1 to 3 are significantly better than those of the high-fat control group, and the synergistic effect of the probiotic combination is further illustrated compared with the comparative examples 1 to 5. The food intake of the example group was slightly lower than that of the high-fat control group, showing a trend of decreasing, but only example 1 had a statistical difference (P < 0.05) from the high-fat control group.
Experimental example 2 clinical trials of probiotic compositions for weight control
And (3) experimental design:
12 overweight and obese patients with BMI > 28 were selected and randomized into probiotic and placebo groups. Subjects consumed 150 hundred million of the probiotic combination formulation of example 1 or placebo per day in combination with appropriate exercise (aerobic exercise for 30-45 minutes per day, at least 3 times per week) for 3 months. Antibiotics treatment was avoided during the experiment and regular follow-up visits checked for compliance with diet and exercise programs via questionnaires. Measuring Body Mass Index (BMI) and waist circumference after 3 months; evaluating metabolic state by detecting serum Triglyceride (TG), total Cholesterol (TC), high density lipoprotein (HDL-C), and low density lipoprotein (LDL-C); detecting free cortisol (UFC) in urine and performing stress state detection by State-trait anxiety Scale (STAI-T) and sensory stress Scale (PSS); and three-factor eating questionnaire (TFEQ), binge eating volume questionnaire (BSQ) were performed for dietary behavior assessment. Calculating the difference (T) of each index of the subjects before and after the edible probiotic combined preparation 12 -T 0 ) The correlation results are shown in FIGS. 1-4. And (3) test results:
the various indexes of the test are shown in the following table:
TABLE 2
Differences from baseline T0 show: * P <0.05; * P <0.01
In the body index test results, the weight (P < 0.05), BMI (P < 0.01) and waist circumference (P < 0.05) of the probiotic groups were all significantly reduced from the baseline period, while the placebo group did not show significant differences. In the metabolic state indexes, triglyceride, total cholesterol and low density lipoprotein are all remarkably reduced (P is less than 0.01), and high density lipoprotein is remarkably improved (P is less than 0.01); while placebo groups did not show significant differences. The scheme is based on weight management of the control of the brain intestinal axis, so that the stress state and the eating behavior are also indexes to be detected. The probiotic group also showed significant reduction in cortisol levels as an indicator of stress (P < 0.01), and the placebo group did not. The probiotic group showed a significant decrease (P < 0.05) in both the status-trait anxiety metric and the questionnaire scores of the perceived stress metric. Questionnaires of dietary behavior showed that the probiotic group significantly increased cognitive restriction inhibition (P < 0.01), significantly reduced uncontrolled feeding and hunger (P < 0.01), and significantly reduced severity and intensity of binge eating (P < 0.01).
Application example 1:
a solid beverage A, having a composition shown in Table 3 below, was prepared by mixing, and had a specification of 2 g/bag and a viable cell specification of 150 hundred million CFU. The probiotic composition is prepared by the raw materials and method of example 1.
TABLE 3 solid beverage formulation
| Raw materials | Number of parts |
| Example 1 probiotic composition | 5 |
| Inulin powder | 20 |
| Erythritol and its preparation method | 63 |
| Fruit powder | 10 |
| Vitamin C | 2 |
Application example 2:
a solid beverage B having a composition shown in Table 4 below was prepared by mixing, and had a specification of 2 g/bag and a viable cell specification of 100 hundred million CFU. The probiotic composition is prepared by the raw materials and the method in the example 2.
TABLE 4 solid beverage formulation
| Starting materials | Number of parts |
| Example 2 probiotic compositions | 5 |
| Bifidobacterium longum R0175 | 3.5 |
| Fructo-oligosaccharide | 30 |
| Galacto-oligosaccharides | 20 |
| Xylitol, its preparation method and use | 40.5 |
| Essence | 1 |
Application example 3:
a capsule is prepared by mixing, dry granulating and encapsulating as shown in Table 5 below, wherein the capsule has a specification of 0.5 g/granule and a viable bacteria specification of 250 hundred million CFU. The probiotic composition is prepared by the raw materials and method of example 3.
TABLE 5 Capsule formulation
Application example 4:
a capsule is prepared by mixing, dry granulating and encapsulating as shown in Table 6 below, with a specification of 0.5 g/capsule and a viable bacteria specification of 90 hundred million CFU. The probiotic composition is prepared by the raw materials and method of example 3.
TABLE 6 Capsule formulation
| Starting materials | Number of copies |
| Example 3 probiotic compositions | 12 |
| Saffron extract | 16 |
| Resistant dextrins | 30 |
| Vitamin C | 8 |
| Maltodextrin | 34 |
Application example 5:
a tabletted candy having a composition shown in Table 7 below was prepared by mixing the components and tabletting with dry granulation, the specification was 0.6 g/tablet, and the viable bacteria specification was 150 hundred million CFU. The probiotic composition is prepared by the raw materials and method of example 1.
TABLE 7 tabletted confectionery formulations
| Starting materials | Number of parts |
| Example 1 probiotic composition | 16.7 |
| Vitamin C | 5 |
| Sorbitol | 57.3 |
| Microcrystalline cellulose | 20 |
| Magnesium stearate | 1 |
Application example 6:
a tabletted candy is prepared by mixing the components shown in Table 8 below, granulating by dry method, and tabletting, wherein the specification is 0.6 g/tablet, and the viable bacteria specification is 120 hundred million CFU. The probiotic composition is prepared by the raw materials and method of example 1.
TABLE 8 tabletted confectionery formulations
| Raw materials | Number of parts |
| Example 1 probiotic composition | 13.3 |
| Green coffee powder | 20 |
| Vitamin C | 5 |
| Sorbitol | 50.7 |
| Microcrystalline cellulose | 10 |
| Magnesium stearate | 1 |
Finally, it should be noted that the above-mentioned contents are only used for illustrating the technical solutions of the present invention, and not for limiting the protection scope of the present invention, and that the simple modifications or equivalent substitutions of the technical solutions of the present invention by those of ordinary skill in the art can be made without departing from the spirit and scope of the technical solutions of the present invention.
Claims (10)
1. A probiotic composition, characterized by: comprises lactobacillus rhamnosus HA-114, lactobacillus helveticus R0052 and bifidobacterium animalis Lafti B94.
2. The probiotic composition according to claim 1, characterized in that: comprises the following components in parts by weight: 50-120 parts of lactobacillus rhamnosus HA-114, 5-50 parts of lactobacillus helveticus R0052 and 5-50 parts of bifidobacterium animalis Lafti B94.
3. The probiotic composition according to claim 1, characterized in that: comprises the following components in parts by weight: 100 parts of lactobacillus rhamnosus HA-114, 30 parts of lactobacillus helveticus R0052 and 20 parts of bifidobacterium animalis Lafti B94.
4. The probiotic composition according to claim 2, characterized in that: the viable count of the probiotic composition is 60-200 hundred million CFU.
5. The probiotic composition according to claim 3, characterized in that: the probiotic composition has a viable count of 150 hundred million CFU.
6. A process for the preparation of a probiotic composition according to any one of claims 1 to 5, characterized in that: the method comprises the following steps:
mixing Lactobacillus rhamnosus HA-114, lactobacillus helveticus R0052, and Bifidobacterium animalis Lafti B94, stirring, and storing.
7. Use of a probiotic composition according to any one of claims 1 to 5 or obtained by the preparation process according to claim 6, for the preparation of a weight management product.
8. Use according to claim 7, characterized in that: the weight management product comprises a beverage, capsule or candy.
9. Use of a probiotic composition according to any one of claims 1 to 5 or obtained by the preparation process according to claim 6, for the preparation of a reduced-pressure product.
10. Use according to claim 9, characterized in that: the reduced-pressure product comprises a beverage, capsule, or candy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211124400.4A CN115404187B (en) | 2022-09-15 | 2022-09-15 | Probiotic composition for weight management and decompression |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211124400.4A CN115404187B (en) | 2022-09-15 | 2022-09-15 | Probiotic composition for weight management and decompression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115404187A true CN115404187A (en) | 2022-11-29 |
| CN115404187B CN115404187B (en) | 2023-07-14 |
Family
ID=84165307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211124400.4A Active CN115404187B (en) | 2022-09-15 | 2022-09-15 | Probiotic composition for weight management and decompression |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115404187B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110140968A (en) * | 2019-06-18 | 2019-08-20 | 广州康泽医疗科技有限公司 | A kind of alleviation anxiety, depression adjust mood deviation, the probiotic composition for depressurizing sleeping and its preparation method and application |
| CN110179121A (en) * | 2019-05-13 | 2019-08-30 | 湖南唯乐可健康产业有限公司 | It is a kind of to improve the 5-linked probiotic composition of enteron aisle, compound solid beverage and its preparation method and application |
| CN113142304A (en) * | 2021-03-29 | 2021-07-23 | 河北一然生物科技有限公司 | Probiotic composition for promoting human body metabolism to generate yellow feces and application thereof |
| US20220072067A1 (en) * | 2019-05-31 | 2022-03-10 | Jiangnan University | Pediococcus acidilactici CCFM6432 for Alleviating Depression, Food Fermented Thereby and Application Thereof |
| WO2022269539A1 (en) * | 2021-06-23 | 2022-12-29 | Danstar Ferment Ag | Method for favoring wellness and facilitating self-control before, during and/or after a restrictive diet |
-
2022
- 2022-09-15 CN CN202211124400.4A patent/CN115404187B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110179121A (en) * | 2019-05-13 | 2019-08-30 | 湖南唯乐可健康产业有限公司 | It is a kind of to improve the 5-linked probiotic composition of enteron aisle, compound solid beverage and its preparation method and application |
| US20220072067A1 (en) * | 2019-05-31 | 2022-03-10 | Jiangnan University | Pediococcus acidilactici CCFM6432 for Alleviating Depression, Food Fermented Thereby and Application Thereof |
| CN110140968A (en) * | 2019-06-18 | 2019-08-20 | 广州康泽医疗科技有限公司 | A kind of alleviation anxiety, depression adjust mood deviation, the probiotic composition for depressurizing sleeping and its preparation method and application |
| CN113142304A (en) * | 2021-03-29 | 2021-07-23 | 河北一然生物科技有限公司 | Probiotic composition for promoting human body metabolism to generate yellow feces and application thereof |
| WO2022269539A1 (en) * | 2021-06-23 | 2022-12-29 | Danstar Ferment Ag | Method for favoring wellness and facilitating self-control before, during and/or after a restrictive diet |
Non-Patent Citations (2)
| Title |
|---|
| NUTRITION INSIGHT: "Lallemand Health Solutions’ L.rhamnosus HA-114 may curb overeating, reduce insulin resistance", pages 1, Retrieved from the Internet <URL:https://www.nutritioninsight.com/news/lallemand-health-solutions-l-rhamnosus-ha-114-may-curb-overeating-reduce-insulin-resistance.html> * |
| 余萍 等: "鼠李糖乳杆菌(H0107)通便效果试验", 《农业科技与装备》, no. 5, pages 48 - 49 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115404187B (en) | 2023-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190151376A1 (en) | Treatment of obesity, the metabolic syndrome, type 2 diabetes, cardiovascular diseases, dementia, alzheimer's disease and inflammatory bowel disease by using at least one bacterial strain from prevotella | |
| EP1945235B1 (en) | Probiotics to influence fat metabolism and obesity | |
| German et al. | The development of functional foods: lessons from the gut | |
| TWI594758B (en) | Composition comprising bifidobacteria,processes for the preparation thereof and uses thereof | |
| EP2991659B1 (en) | Lachnospiraceae in the gut microbiota and association with body weight | |
| CN104413334A (en) | Edible composition as well as preparation method and application thereof | |
| CN111035014A (en) | Probiotic preparation and preparation method thereof | |
| JP2000175615A (en) | Symbiotic functional food | |
| WO2019189200A1 (en) | Nutritional composition, food/drink composition using nutritional composition, and modified milk powder using nutritional composition | |
| Gyawali et al. | The role of prebiotics in disease prevention and health promotion | |
| US20210330719A1 (en) | Probiotic combination for treatment of inflammatory-related gastrointestinal disorders | |
| CN111557404A (en) | Digestion-aiding probiotic solid beverage and preparation method thereof | |
| US20220000947A1 (en) | Probiotic combination for treatment of allergic disorders | |
| CN104415062A (en) | Application of mixture containing four lactic acid bacteria strains in prevention and/or relieving of alcoholic liver diseases | |
| TW201705969A (en) | Novel Lactobacillus mali APS1 and use thereof | |
| WO2024149132A1 (en) | Probiotic protein multivitamin and preparation method therefor | |
| Kouamé et al. | New insights into functional cereal foods as an alternative for dairy products: a review | |
| Pop et al. | Pro and prebiotics foods that modulate human health | |
| CN108523123A (en) | A kind of full nutritional support food of diabetes | |
| CN109965290B (en) | Meal replacement powder for improving intestinal flora and application thereof | |
| CN115404187B (en) | Probiotic composition for weight management and decompression | |
| Kumar et al. | Health-promoting probiotic functional foods | |
| CN106974940B (en) | Application of probiotics of scleritis in treating and preventing obesity and related diseases | |
| TWI844535B (en) | Use of Bifidobacterium breve MCC1274, method for screening Bifidobacterium bacteria with anti-obesity effect, and method for screening responders to Bifidobacterium bacteria with anti-obesity effect | |
| CN115989832B (en) | Functional high-viable-count probiotic-flavored fermented milk and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |